Risk of Hypertension, Acute Myocardial Infarction, and Stroke in Migraine Patients Treated With Migraine Preventive Medications (20200403)

Study identification

• EU PAS number:
  EUPAS45799
• Study ID:
  47658
• Official title and acronym:
  Risk of Hypertension, Acute Myocardial Infarction, and Stroke in Migraine Patients Treated With Migraine Preventive Medications (20200403)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

NoviSci Durham, NC, USA

Study timelines

Date when funding contract was signed

Planned: 15/02/2022

Actual: 15/02/2022

Study start date

Planned: 31/03/2022

Actual: 31/03/2022

Data analysis start date

Planned: 01/06/2022

Actual: 09/06/2022

Date of final study report

Planned: 01/06/2023

Actual: 01/06/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen, Novartis

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable